Navigation Links
New Data Show Once-Daily INTUNIV(TM) (guanfacine) Extended Release Tablets Demonstrated Significant ADHD Symptom Reduction when Assessed Using the Oppositional Subscale of the Conners' ADHD Rating Scale
Date:10/29/2009

HONOLULU, Oct. 29 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, announced new study results on INTUNIV(TM) (guanfacine) Extended Release Tablets, at a major psychiatric medical meeting today. The primary objective of this study was to assess the change from baseline on the oppositional subscale of the Conners' Parent Rating Scale-Revised: Long Form (CPRS-R:L) in patients ages 6 to 12 with a primary diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) with the presence of oppositional symptoms at baseline. INTUNIV met the primary objective demonstrating significant efficacy in reducing symptoms as measured by the oppositional subscale. Some of the symptoms measured by this scale include deliberately doing things that annoy others, refusing to comply with adults' requests, and being touchy or easily annoyed by others.

According to the Centers for Disease Control and Prevention (CDC), approximately 7.8 percent of all US school-aged children have been diagnosed with ADHD at some point in their lives. ADHD is a complex neurobehavioral disorder, which includes symptoms and behaviors such as inattentiveness, running around or climbing excessively, and being excitable or impulsive, many of which can be disruptive.

"The disruptive nature of ADHD can impact social and academic settings for those patients diagnosed with the disorder," said F. Randy Sallee, MD, PhD, Professor of Psychiatry at the University of Cincinnati and Cincinnati Children's Hospital Medical Center in Cincinnati, Ohio. "This study showed that INTUNIV is an effective option for treating a
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
2. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
3. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
4. ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
5. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
6. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
7. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
8. ISTA Pharmaceuticals Announces Results of Clinical Trial of Xibrom(TM) QD (Once-Daily) Formulation
9. New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
10. Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
11. U.S. FDA Approves Requip(R) XL(TM), the First and Only Oral Once-Daily Non-Ergot Dopamine Agonist for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... NORTHBROOK, Ill. , July 22, 2014 /PRNewswire/ ... has announced that the U.S. Food and Drug ... standards as consensus standards for medical devices incorporating ... UL 2054 - Standard for Household and Commercial ... Batteries (Cells). Consensus standards are ...
(Date:7/22/2014)... WASHINGTON, New York , July ... Neue Partnerschaft für umfassenden Schutz ... Medikamenteneinwirkungen in Österreich    ... Anbieter von geschlossenen Transfersystemen (Closed System Transfer Devices, CSTDs) ... Medikus , einen Vertriebshändler und Hersteller ...
(Date:7/21/2014)... July 21, 2014 Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... results for the second quarter of fiscal year 2014 ... hold a conference call to discuss its financial results ... 1:30 p.m., Pacific Daylight Time (4:30 p.m., Eastern Daylight ...
Breaking Medicine Technology:Two UL Battery Safety Standards Are now FDA Recognized Consensus Standards for Medical Devices 2Equashield ernennt Medikus zu seinem exklusiven österreichischen Vertriebspartner für seine geschlossenen Arzneimitteltransfersysteme 2Thoratec Schedules Second Quarter Conference Call, Webcast 2
(Date:7/22/2014)... (PRWEB) July 22, 2014 The Entertainment ... in providing resources, educational tools and recognition activities for ... stories of prevention, treatment and recovery. On July 24, ... will spotlight some of these resources with a special ... Administration helpline and treatment website at the end of ...
(Date:7/22/2014)... 22, 2014 The market for botulinum ... few years, owing to novel medical indications created and ... the aging societies where physical appearance is extremely valued. ... player, current competitors, new companies and technologies are setting ... BoNTs will put the price of 1st-gen products under ...
(Date:7/22/2014)... Kathleen Doheny HealthDay Reporter ... uterus with a minimally invasive procedure known as morcellation carries ... study pinpoints the likelihood more clearly. Twenty-seven of every ... at the time of the procedure, researchers found, with the ... Surgeons performing a hysterectomy with morcellation use a power ...
(Date:7/22/2014)... . Montreal, July ... out for a cigarette twice as often as smokers who ... have the hardest time shaking off the habit may have ... , Those insights were among the collective findings recently published ... a team of researchers based in part at Concordia University. ...
(Date:7/22/2014)... July 22, 2014 5i Sciences, a ... the appointment of Molly Coye, M.D., M.P.H. to a ... internationally renowned authority on the market introduction of innovative ... that she will advise on strategies for building a ... cNEP® technology. Dr. Coye is currently the Chief ...
Breaking Medicine News(10 mins):Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 2Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 3Health News:Botulinum Neurotoxins Marketplace Analysed in New La Merie Publishing Report Available at MarketPublishers.com 4Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:Extra exercise helps depressed smokers kick the habit faster 2Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2
... and parts of Wales. Breast cancer patients from England must ... women get it for free. // ,This discrimination arose ... for Herceptin for early stage breast cancer sufferers until the ... as all Welsh Local Health Boards have agreed to pay ...
... case in the capital of Zagreb it was revealed that a ... bird flu virus. //, ,The location of the dead swan ... last weekend. Tests confirmed that the dead bird had contracted the ... whether it was the lethal H5N1 strain would be released on ...
... observing participants at a simulated investment game, a ... and sustained motivation while working //collectively in a ... ,The study conducted by the University ... of targets among teams, when ‘punishments’ became a ...
... prepared to pledge more money to combat bird flu as ... and Asian donors had pledged $1.9 billion in January, during ... containment and prevention methods in 12 countries, mostly in Asia. ... world through migratory birds, including infections in at least five ...
... and newborns should avoid exposure to the fumes of ... contain dyes and lacquers//, could give rise to allergies ... specialist at Germany's environmental agency. ,Pregnant women ... professionals and stay clear of the work area altogether. ...
... Research Institute has warned the nation's betel-nut chewers of ... other detrimental habits like smoking and drinking. ... at the National Health Research Institute when betel nut ... of developing cancer of the esophagus was about 195 ...
Cached Medicine News:Health News:Free Herceptin Treatment for Those Who Live Over the Welsh Border 2Health News:Motivation Yardstick: Rewards or Punishment? Discover the Superior Performance Trigger 2Health News:Cancer Risks for Betel Nut Chewers 2
... The Techne TC-512 has a graphical touch ... your experiments at the "touch of a ... Wide linear gradient, Touch Screen, Graphical Display, ... Performance, Versatile Block Format, Intuitive Programmin, Free ...
... high performance, high sample throughput instrument at a ... Flexible block format, a newly designed flexible ... Includes a four year or 80,000 Cycle ... be connected and run through a PC using ...
... MyGenie 32 Thermal Block has a compact ... or lower temperatures rapidly, and can handle up to ... the lid, so there is no need to add ... Up to 100 programs can be stored, and up ...
... cycler is the smallest footprint two-bay thermal ... ever before. The Disciple instrument ... communications to a computer using a remote ... thermal cycler contains the latest in power ...
Medicine Products: